Amgen Overview

  • Year Founded
  • 1980

Year Founded

  • Status
  • Public

  • Employees
  • 26,700


  • Stock Symbol
  • AMGN

Stock Symbol

  • Investments
  • 69

  • Share Price
  • $300.70
  • (As of Tuesday Closing)

Amgen General Information


Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Other Industries
Other Pharmaceuticals and Biotechnology
Drug Discovery
Stock Exchange
Corporate Office
  • One Amgen Center Drive
  • Thousand Oaks, CA 91320-1799
  • United States
+1 (805) 000-0000

Amgen Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Amgen Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$300.70 $304.72 $216.93 - $329.72 $161B 536M 2.6M $7.03

Amgen Financials Summary

In Thousands,
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 206,041,462 179,868,975 167,365,243 151,375,930
Revenue 29,532,000 28,190,000 26,323,000 25,979,000
EBITDA 12,071,000 14,615,000 12,013,000 11,142,000
Net Income 3,763,000 6,717,000 6,552,000 5,893,000
Total Assets 92,980,000 97,154,000 65,121,000 61,165,000
Total Debt 64,020,000 64,613,000 38,945,000 33,309,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Amgen Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Amgen‘s full profile, request access.

Request a free trial

Amgen Comparisons

HQ Location
Total Raised
Post Valuation
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and A
Thousand Oaks, CA
26,700 As of 2023
000000000 000.00

000 00

ion ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dol
Indianapolis, IN
00000 As of 0000
000000000 00 000.00


onsectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
0000 000000000
Foster City, CA
00000 As of 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Amgen Competitors (30)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Eli Lilly and Company Corporation Indianapolis, IN 00000 000.00 000000000 00 000.00
Gilead Sciences Formerly VC-backed Foster City, CA 00000 000.00 0000
Bristol-Myers Squibb Private Debt Financed Princeton, NJ 00000 000.00 000000000 000.00
Regeneron Pharmaceuticals Formerly VC-backed Tarrytown, NY 00000 00.000 000000000000 00.000
AbbVie Corporation North Chicago, IL 00000 000.00 000000000 000.00
You’re viewing 5 of 30 competitors. Get the full list »

Amgen Patents

Amgen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240105341-A1 Systems and methods for estimating tumor growth Pending 22-Sep-2022 000000000
US-20240085864-A1 Just-in-time learning with variational autoencoder for cell culture process monitoring and/or control Pending 14-Sep-2022 00000000000
US-20240076604-A1 Large scale bioreactor system and method Pending 06-Sep-2022 000000000
US-20240076709-A1 Lean perfusion cell culture methods Pending 06-Sep-2022 0000000000
US-20240078711-A1 Systems and methods for lossless line fit data compression Pending 01-Sep-2022 G06T9/001
To view Amgen’s complete patent history, request access »

Amgen Executive Team (104)

Name Title Board Seat Contact Info
Robert Bradway Chief Executive Officer & Chairman
Peter Griffith Executive Vice President, Finance and Chief Financial Officer
David Reese Ph.D Chief Technology Officer & Executive Vice President of Research and Development
Nancy Grygiel JD Senior Vice President, Worldwide Compliance & Business Ethics and Chief Compliance Officer
Mike Zahigian Senior Vice President & Chief Information Officer
You’re viewing 5 of 104 executive team members. Get the full list »

Amgen Board Members (22)

Name Representing Role Since
000 00000 Self Board Member, Member of the Audit Committee & Governance and Nominating Committee 000 0000
00000 000000 00 Self Board Member, Member of the Compensation and Management Development Committee & Corporate Responsibility and Compliance Committee 000 0000
0000000 000000 00. Self Board Member 000 0000
00000 0000000 Self Board Member, Member of Audit Committee & Governance and Nominating Committee 000 0000
0000 0000000 Amgen Board Member, Member of the Compensation and Management Development Committee & Governance and Nominating Committee 000 0000
You’re viewing 5 of 22 board members. Get the full list »

Amgen Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Amgen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Amgen‘s full profile, request access.

Request a free trial

Amgen Investments & Acquisitions (69)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
BioAge 01-Feb-2024 00000 0000 00000 Drug Discovery
Quantinuum 16-Jan-2024 00000 0000 00000 Application Specific Semiconductors
Horizon Therapeutics 06-Oct-2023 0000000000 000.00 Pharmaceuticals 000000 00
Generate Biomedicines 06-Sep-2023 00000 0000 00000 Biotechnology
Chemocentryx 20-Oct-2022 Merger/Acquisition 00.000 Pharmaceuticals 000000 00
You’re viewing 5 of 69 investments and acquisitions. Get the full list »

Amgen Subsidiaries (8)

Company Name Industry Location Founded
Amgen Astellas BioPharma Drug Discovery Tokyo, Japan 2013
Horizon Therapeutics Pharmaceuticals Dublin, Ireland 0000
Amgen Ventures Corporate Venture Capital Thousand Oaks, CA 0000
Amgen Safety Net Foundation Foundation Thousand Oaks, CA 0000
Chemocentryx Pharmaceuticals Mountain View, CA 0000
You’re viewing 5 of 8 subsidiaries. Get the full list »

Amgen ESG

Risk Overview

Risk Rating

Updated May, 31, 2024

22.56 | Med Risk

Risk Scale

A lower score indicates better sustainability












Exposure refers to the extent to which a company is exposed to different material ESG issues



Management is related to actions taken to manage ESG issues


Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.


Covered Companies

00 of 16,191






00 of 921






00 of 405




To view Amgen’s complete esg history, request access »

Amgen Exits (21)

Company Name Exit Date Exit Type Exit Size Status Buyers
Jasper Therapeutics 24-Sep-2021 0000 00000 Completed
  • 13 buyers
SomaLogic 25-Nov-2020 00 000000000000000 00000 Completed
  • 22 buyers
Carmot Therapeutics 30-Sep-2020 00000 00000 00 000.00 Completed
  • 3 buyers
Provention Bio 24-Sep-2019 0000 0000 Completed
  • 00000
allerguard 01-Sep-2019 Seed Round 00.00 Completed
  • 7 buyers
You’re viewing 5 of 21 exits. Get the full list »

Amgen FAQs

  • When was Amgen founded?

    Amgen was founded in 1980.

  • Who is the CEO of Amgen?

    Robert Bradway is the CEO of Amgen.

  • Where is Amgen headquartered?

    Amgen is headquartered in Thousand Oaks, CA.

  • What is the size of Amgen?

    Amgen has 26,700 total employees.

  • What industry is Amgen in?

    Amgen’s primary industry is Biotechnology.

  • Is Amgen a private or public company?

    Amgen is a Public company.

  • What is Amgen’s stock symbol?

    The ticker symbol for Amgen is AMGN.

  • What is the current stock price of Amgen?

    As of 11-Jun-2024 the stock price of Amgen is $300.70.

  • What is the current market cap of Amgen?

    The current market capitalization of Amgen is $161B.

  • What is Amgen’s current revenue?

    The trailing twelve month revenue for Amgen is $29.5B.

  • Who are Amgen’s competitors?

    Eli Lilly and Company, Gilead Sciences, Bristol-Myers Squibb, Regeneron Pharmaceuticals, and AbbVie are some of the 30 competitors of Amgen.

  • What is Amgen’s annual earnings per share (EPS)?

    Amgen’s EPS for 12 months was $7.03.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »